The Medicines Patent Pool signed a royalty-free license agreement with AbbVie to enable quality-assured manufacturers to develop and sell generic medicines including Mavyret, according to a press release.
The license agreement for a generic of Mavyret (glecaprevir/pibrentasvir, AbbVie) was launched at The Liver Meeting 2018 and includes 95 countries and four territories that are low- or middle-income.
“[Glecaprevir/pibrentasvir] is a priority therapy for licensing for the [Medicines Patent Pool], so this agreement with AbbVie is very good news for public health,” Marie-Paule Kieny, PhD, chair of the Medicines Patent Pool (MPP) governance board, said in the release. “It is a really important new option for a significant proportion of HCV patients throughout the world. As with previous MPP licenses, we look forward to facilitating access to generic versions of this product as quickly as possible in as many territories as possible.”
Recent data presented at The Liver Meeting showed that the pangenotypic regimen yielded nearly perfect SVR rates after 8 weeks of therapy in patients with HCV and compensated cirrhosis. Glecaprevir/pibrentasvir also demonstrated an SVR rate of 97% in a real-world study.